NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $18.79 +0.25 (+1.35%) (As of 11/25/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARWR alerts:Sign Up Key Stats Today's Range$18.73▼$19.8450-Day Range$17.70▼$21.9752-Week Range$17.05▼$39.83Volume1.51 million shsAverage Volume1.20 million shsMarket Capitalization$2.34 billionP/E RatioN/ADividend YieldN/APrice Target$45.33Consensus RatingModerate Buy Company OverviewArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Read More… This Crisis Could Be Worse Than 2008 (Ad)Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America is teetering on the edge of a collapse unlike anything we've seen.In my new book, "Midnight in America," I expose the hidden deals between Washington and Wall Street. Arrowhead Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks72nd Percentile Overall ScoreARWR MarketRank™: Arrowhead Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 298th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageArrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($4.31) to ($3.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 7.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arrowhead Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.55% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 0.64%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.55 Percentage of Shares Shorted7.55% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 0.64%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.20 News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Arrowhead Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Stock News HeadlinesArrowhead climbs after licensing deal with SareptaNovember 26 at 8:42 AM | msn.comSarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA ProgramsNovember 26 at 7:00 AM | businesswire.comIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is making headlines for last week's new earnings report – which revealed the AI juggernaut nearly doubled their profits in the last year alone.November 26, 2024 | Chaikin Analytics (Ad)Reviewing PaxMedica (NASDAQ:PXMD) & Arrowhead Pharmaceuticals (NASDAQ:ARWR)November 25 at 2:53 AM | americanbankingnews.comAnalysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $45.33November 25 at 1:41 AM | americanbankingnews.comArrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on TuesdayNovember 25 at 1:06 AM | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC WainwrightNovember 24 at 3:45 AM | americanbankingnews.comArrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to AnalystsNovember 22, 2024 | msn.comSee More Headlines ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $30.60 at the beginning of the year. Since then, ARWR stock has decreased by 38.6% and is now trading at $18.79. View the best growth stocks for 2024 here. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.80. The business's revenue was down 100.0% on a year-over-year basis. Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' top institutional shareholders include State Street Corp (5.11%), FMR LLC (4.88%), Geode Capital Management LLC (2.38%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.73%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, Hongbo Lu, Victoria Vakiener, William D Waddill and Adeoye Y Olukotun. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX). Company Calendar Last Earnings8/08/2024Today11/26/2024Next Earnings (Confirmed)11/26/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees400Year FoundedN/APrice Target and Rating Average Stock Price Target$45.33 High Stock Price Target$62.00 Low Stock Price Target$27.00 Potential Upside/Downside+141.3%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($4.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,270,000.00 Net MarginsN/A Pretax Margin-2,792.41% Return on Equity-152.95% Return on Assets-63.93% Debt Debt-to-Equity RatioN/A Current Ratio4.65 Quick Ratio4.65 Sales & Book Value Annual Sales$19.65 million Price / Sales118.89 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book7.01Miscellaneous Outstanding Shares124,315,000Free Float118,721,000Market Cap$2.34 billion OptionableOptionable Beta0.93 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:ARWR) was last updated on 11/26/2024 by MarketBeat.com Staff From Our PartnersJ.D. Vance: Wall Street Will Tank Bonds to Sabotage TrumpJ.D. Vance just dropped a bombshell: With Trump in office, Wall Street could drive the bond market into a deat...Golden Crest | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredWarren Buffett Is Sitting on $278 Billion in Cash—Should You Be Worried?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.